I went and looked at just the straight Cytodyn conference calls, excluding the Wall Street reporter stuff. They went something like December (deal with Vyera), beginning of February, beginning of March, Mid April, late May, and now fast on the heels of that May call is this one. That abnormally fast turnaround time when so many important things hang in the balance is why I’m thinking at least one substantial catalyst. It makes the most sense that it is either uplist or finance-related. Getting NASH money, licensing overseas, a major bank deal, or some sort of money to fuel this ship. I do think uplisting could be tied to this as we are in the sweet spot time-wise for when NP said we’d here more. But even thing he had said we satisfy all criteria for the NYSE it does seem like money is the big hurdle for that and every other next step. So maybe it’s a one-two punch. We signed a deal for X dollars and with that in place we have submitted our application to the NYSE. Outside of that I just can’t see anything “major” requiring a turnaround this fast from the last call.